Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 /g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 Q2 2025 REVENUE OF 103.0 MILLION FOR YORVIPATH  AND 50.7 MILLION FOR SKYTROFA   TRANSCON  CNP (NAVEPEGRITIDE) NDA UNDER PRIORITY REVIEW FOR THE TREATMENT OF CHILDREN WITH ACHONDROPLASIAWITH PDUFA DATE OF NOVEMBER 30, 2025  SKYTROFA  (LONAPEGSOMATROPIN-TCGD) APPROVED IN THE U.S. FOR TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY; FIRST OF MANY PLANNED LABEL EXPANSIONS  WEEK 26 INTERIM RESULTS FOR COACH TRIAL HIGHLIGHT THE UNIQUE PORTFOLIO OF ONCE-WEEKLY TRANSCON CNP AND ONCE-WEEKLY TRANSCON HGH, WITH COMPLEMENTARY MODES OF ACTION, TO POTENTIALLY FURTHER TRANSFORM THE TREATMENT LANDSCAPE FOR GROWTH DISORDERS AND PHYSICAL FUNCTIONING CONFERENCE CALL TODAY AT 4:30 PM ET COPENHAGEN, AUG. 07, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE. WITH THE ROBUST GLOBAL UPTAKE OF YORVIPATH AND WITH TRANSCON CNP UNDER U.S. FDA PRIORITY REVIEW, ASCENDIS IS ON THE VERGE OF BRINGING OUR THIRD HIGH-VALUE MEDICINE TO PATIENTS AND SUBSTANTIALLY TRANSFORMING OUR FINANCIAL PROFILE, SAID JAN MIKKELSEN, ASCENDIS PHARMA'S PRESIDENT AND CHIEF EXECUTIVE OFFICER.

ASCENDIS PHARMA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

COPENHAGEN, DENMARK, JULY 31, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED IT WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON THURSDAY, AUGUST 7, 2025, AFTER THE CLOSE OF THE U.S. FINANCIAL MARKETS. ASCENDIS PHARMA WILL ALSO HOST A CONFERENCE CALL AND LIVE WEBCAST ON AUGUST 7, 2025, AT 4:30 P.M.

ASCENDIS PHARMA TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON AUGUST 7, 2025

FIRST OF MANY PLANNED LABEL EXPANSIONS SUPPORTING VISION 2030 GOAL TO BECOME THE LEADING ENDOCRINOLOGY RARE DISEASE COMPANY ON TRACK TO INITIATE BASKET TRIAL FOR ISS, SHOX DEFICIENCY, TURNER SYNDROME, AND SGA*, AS WELL AS COMBINATION THERAPY TRIALS IN ACHONDROPLASIA AND HYPOCHONDROPLASIA, IN Q4 2025 COPENHAGEN, DENMARK, JULY 28, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED THAT THE U.S. FOOD & DRUG ADMINISTRATION (FDA) HAS APPROVED SKYTROFA (LONAPEGSOMATROPIN-TCGD; DEVELOPED AS TRANSCON HGH) FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY (GHD), A RARE DISORDER RESULTING FROM DECREASED OR TOTAL LOSS OF GROWTH HORMONE PRODUCTION. LONAPEGSOMATROPIN (APPROVED BY THE FDA IN 2021 FOR THE TREATMENT OF PEDIATRIC GHD) IS A PRODRUG OF SOMATROPIN (HUMAN GROWTH HORMONE, OR HGH) ADMINISTERED ONCE WEEKLY, PROVIDING SUSTAINED RELEASE OF ACTIVE, UNMODIFIED SOMATROPIN.

FDA APPROVES SKYTROFA (LONAPEGSOMATROPIN-TCGD) FOR THE ONCE-WEEKLY TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY

COPENHAGEN, DENMARK, JULY 14, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED NEW DATA FROM WEEK 156 OF ITS PHASE 3 PATHWAY TRIAL CONFIRMING THAT LONG-TERM TREATMENT WITH TRANSCON PTH (PALOPEGTERIPARATIDE) CONTINUED TO PROVIDE A DURABLE RESPONSE IN ADULTS WITH HYPOPARATHYROIDISM REGARDLESS OF ITS CAUSE (POST-SURGICAL, AUTOIMMUNE, GENETIC, OR IDIOPATHIC), INCLUDING IMPROVEMENTS IN BIOCHEMISTRIES, KIDNEY FUNCTION, AND QUALITY OF LIFE. RESULTS WERE SHARED OVER THE WEEKEND IN AN ORAL PRESENTATION BY ALIYA KHAN, M.D.

NEW 3-YEAR PHASE 3 DATA CONFIRMED SUSTAINED RESPONSE TO TRANSCON PTH (PALOPEGTERIPARATIDE) THERAPY IN ADULTS WITH HYPOPARATHYROIDISM, INCLUDING IMPROVEMENTS IN BIOCHEMISTRIES, KIDNEY FUNCTION, AND QUALITY OF LIFE

COPENHAGEN, DENMARK, JULY 07, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED TWO ORAL PRESENTATIONS AT ENDO 2025, THE ANNUAL MEETING OF THE ENDOCRINE SOCIETY BEING HELD JULY 12-15, 2025, IN SAN FRANCISCO. DR. ALIYA KHAN WILL PRESENT NEW DATA FROM WEEK 156 OF THE COMPANY'S PHASE 3 PATHWAY TRIAL DEMONSTRATING THE SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH TRANSCON PTH (PALOPEGTERIPARATIDE) IN ADULTS WITH HYPOPARATHYROIDISM  INCLUDING MAINTENANCE OF SERUM AND URINE BIOCHEMISTRIES WITHIN NORMAL LEVELS AND SUSTAINED IMPROVEMENT IN RENAL FUNCTION. DR. CARLOS BACINO WILL PRESENT ADDITIONAL SAFETY AND TOLERABILITY DATA FROM WEEK 52 OF THE COMPANY'S PIVOTAL APPROACH TRIAL OF ONCE-WEEKLY TRANSCON CNP (NAVEPEGRITIDE) IN CHILDREN WITH ACHONDROPLASIA.

ASCENDIS TO SHARE ITS LATEST ENDOCRINOLOGY RARE DISEASE DATAAT ENDO 2025

- FOR THE TRANSCON CNP TREATMENT-NAVE COHORT, COMBINATION TREATMENT RESULTED IN MEAN ANNUALIZED GROWTH VELOCITY (AGV) OF 9.14 CM/YEAR, WITH AN IMPROVEMENT IN MEAN ACH HEIGHT Z-SCORE OF +0.53 OVER 26 WEEKS - FOR THE TRANSCON CNP-TREATED COHORT, COMBINATION TREATMENT RESULTED IN MEAN AGV OF 8.25 CM/YEAR, WITH AN IMPROVEMENT IN MEAN ACH HEIGHT Z-SCORE OF +0.44 OVER 26 WEEKS - THE COMBINATION OF TRANSCON HGH AND TRANSCON CNP DEMONSTRATED ACCELERATED IMPROVEMENT IN BODY PROPORTIONALITY AT WEEK 26, ALIGNING WITH THE INCREASE IN LINEAR GROWTH - SAFETY AND TOLERABILITY DATA CONSISTENT WITH THOSE OBSERVED FOR TRANSCON HGH AND TRANSCON CNP MONOTHERAPIES; COMBINATION TREATMENT WAS GENERALLY WELL TOLERATED, WITH GENERALLY MILD TREATMENT-EMERGENT ADVERSE EVENTS (TEAES) - ASCENDIS TO HOST CONFERENCE CALL TODAY AT 8:00 AM ET COPENHAGEN, DENMARK, JUNE 09, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED WEEK 26 INTERIM ANALYSIS RESULTS FROM ITS ONGOING COACH TRIAL, THE FIRST CLINICAL TRIAL TO EVALUATE COMBINATION TREATMENT WITH ONCE-WEEKLY INVESTIGATIONAL TRANSCON CNP (NAVEPEGRITIDE) AND ONCE-WEEKLY TRANSCON HGH (LONAPEGSOMATROPIN) IN CHILDREN WITH ACHONDROPLASIA. RESULTS DEMONSTRATED THAT TRANSCON HGH BOOSTED TREATMENT BENEFITS OF TRANSCON CNP, RESULTING IN SIGNIFICANT GROWTH AND PROPORTIONALITY IMPROVEMENTS IN CHILDREN WITH ACHONDROPLASIA AFTER 26 WEEKS OF COMBINATION TREATMENT, WITH A SAFETY AND TOLERABILITY PROFILE CONSISTENT WITH THOSE OBSERVED FOR TRANSCON HGH AND TRANSCON CNP MONOTHERAPIES.

TRANSCON HGH BOOSTED TREATMENT BENEFITS OF TRANSCON CNP IN CHILDREN WITH ACHONDROPLASIA AT WEEK 26 INTERIM ANALYSIS OF THE PHASE 2 COACH TRIAL

 ONCE-WEEKLY TRANSCON CNP DEMONSTRATED SIGNIFICANTLY HIGHER ANNUALIZED GROWTH VELOCITY, THE PRIMARY ENDPOINT, COMPARED TO PLACEBO

FDA ACCEPTS TRANSCON CNP NDA FOR PRIORITY REVIEW

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS NEWSWIRE / MAY 20, 2025 / CERRADO GOLD INC. ("CERRADO") (TSXV:CERT)(OTCQX:CRDOF) AND ASCENDANT RESOURCES INC. (TSX:ASND)(OTCQB:ASND) ("ASCENDANT" OR THE "COMPANY") ARE PLEASED TO ANNOUNCE THE SUCCESSFUL COMPLETION OF THE PREVIOUSLY ANNOUNCED PLAN OF ARRANGEMENT (THE "ARRANGEMENT") UNDER THE BUSINESS CORPORATIONS ACT (ONTARIO) PURSUANT TO WHICH CERRADO HAS ACQUIRED ALL OF THE ISSUED AND OUTSTANDING COMMON SHARES OF ASCENDANT ("ASCENDANT SHARES") THAT IT DID NOT ALREADY OWN. THE ARRANGEMENT WAS CARRIED OUT PURSUANT TO THE TERMS OF THE ARRANGEMENT AGREEMENT BETWEEN ASCENDANT AND CERRADO DATED FEBRUARY 3, 2025, AS AMENDED, (THE "ARRANGEMENT AGREEMENT") AND BECAME EFFECTIVE ON MAY 16, 2025, RESULTING IN ASCENDANT BECOMING A WHOLLY OWNED SUBSIDIARY OF CERRADO.

CERRADO GOLD AND ASCENDANT RESOURCES ANNOUNCE COMPLETION OF BUSINESS COMBINATION TRANSACTION

COPENHAGEN, DENMARK, MAY 13, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED NEW DATA SHOWING IMPROVEMENTS IN GROWTH AND BONE MORPHOMETRY FROM WEEK 52 OF ITS PIVOTAL APPROACH TRIAL OF TRANSCON CNP (NAVEPEGRITIDE) IN CHILDREN WITH ACHONDROPLASIA. TRANSCON CNP IS AN INVESTIGATIONAL PRODRUG OF C-TYPE NATRIURETIC PEPTIDE (CNP) ADMINISTERED ONCE WEEKLY PROVIDING CONTINUOUS EXPOSURE OF ACTIVE CNP TO RECEPTORS ON TISSUES THROUGHOUT THE BODY, INCLUDING GROWTH PLATES AND SKELETAL MUSCLE.

NEW DATA SHOWS IMPROVEMENTS IN GROWTH AND BONE MORPHOMETRY IN CHILDREN WITH ACHONDROPLASIA TREATED WITH TRANSCON CNP (NAVEPEGRITIDE)

COPENHAGEN, DENMARK, MAY 12, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOUNCED NEW DATA FROM WEEK 214 OF ITS PHASE 2 PATH FORWARD TRIAL SHOWING THAT LONG-TERM TREATMENT WITH TRANSCON PTH (PALOPEGTERIPARATIDE) CONTINUED TO PROVIDE A DURABLE RESPONSE IN ADULTS WITH HYPOPARATHYROIDISM. RESULTS WERE SHARED IN AN ORAL PRESENTATION TODAY BY ANDREA PALERMO, M.D., FROM THE CAMPUS BIO-MEDICO UNIVERSITY (ROME), DURING ESPE & ESE 2025, THE JOINT CONGRESS OF THE EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY (ESPE) AND THE EUROPEAN SOCIETY OF ENDOCRINOLOGY (ESE).

Ascendis Pharma A/S

ASND

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Ascendis Pharma A/S

ASND.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ASND